Liver Fibrosis and CVD
Modified Look-Locker T1-mapping (MOLLI) magnetic resonance imaging (MRI) allows for direct quantification of T1 relaxation time with a single breath-hold acquisition that reflects tissue composition. 16 T1-mapping MRI has been extensively used to characterize myocardial fibrosis and its adverse consequences. [17] [18] [19] T1-mapping MRI-derived indices also correlate with the stage of liver fibrosis in clinical studies and simulation models. [20] [21] [22] [23] [24] [25] In this study, we evaluate the relationship of early-stage subclinical liver fibrosis estimated by T1-mapping MRI with history of CVD events and detailed phenotyping of cardiac structure and function in a free-living population.
Methods
The data and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, the analytic methods are described in detail in this article.
Study Population
The design of MESA (Multi-Ethnic Study of Atherosclerosis) has been described previously. 26 In brief, MESA is a multiethnic (white, black, Hispanic, and Chinese) prospective cohort of 6814 men and women aged 45 to 84 years and free of overt CVD at enrollment (2000) (2001) (2002) recruited from 6 field centers across the United States to investigate the natural history of subclinical CVD. On enrollment (baseline), and 10 years later (Y10 MESA exam), MESA participants underwent cine and tagged cardiac MRI in addition to clinical questionnaires, physical examinations, and laboratory tests. The Y10 MESA exam MRI protocol (2010-2012) also included native T1-mapping MRI (covering both liver and myocardium) in 2489 participants from 5 of 6 field centers. Of those, 1345 eligible participants (based on glomerular filtration rate ≥45 mL/min, 60 mL/min for one site; and no history of allergic reaction to contrast agents) consented to receive 0.15 mmol/kg of Magnevist (Gd-diethylenetriamine pentaacetic acid; Bayer Healthcare Pharmaceuticals, NJ) and underwent postcontrast T1-mapping MRI. After excluding the images with inadequate quality or lack of liver coverage, native and postcontrast T1-mapping data at the Y10 MESA exam were available in 2087 and 1234 participants, respectively, which were included in this study ( Figure 1 ). MESA participants also underwent noncontrast computed tomography for assessment of coronary artery calcium (CAC) score at baseline and Y10 MESA exam. Computed tomographic images at baseline MESA exam were also used for assessment of liver fat content. Eight hundred and ninety-five MESA participants died before the Y10 MESA exam (16.6% CHD and stroke, 6.7% noncoronary CVD, 73% non-CVD, and 3.8% unknown cause of death or pending adjudication). Institutional review boards at each field center approved the study protocol, and all participants gave written informed consent.
MRI Acquisition
MRI at Y10 MESA exam was performed using 1.5-T scanners (Avanto and Espree; Siemens Medical Systems) with a 6-channel anterior phased array torso coil and corresponding posterior coil elements. Cine images for assessment of left atrial (LA) and LV structure and function included a 4-chamber and a 2-chamber view and a stack of 12 short-axis slices from above the mitral valve to the LV apex with retrospective gating using a steady-state free precession sequence. 17 For assessment of fibrosis, a native (precontrast) MOLLI T1-mapping image was acquired that covered both the heart and liver and was repeated at 12 and 25 minutes after the gadolinium contrast injection. The MOLLI sequence was acquired as a set of 11 source images in 17 heartbeats in 1 breath-hold using 3 consecutively inversion recovery-prepared ECG-synchronized Look-Locker trains. All images were acquired with the same trigger, voxel size, and image position but had different effective inversion times allowing for reconstruction of a parametric T1 map. 19 The MOLLI scan parameters were field of view 360×360 mm 2 , flip angle 35°, repetition time 3.9 ms, echo time 1.95 ms, matrix size 256×192, and slice thickness 8 mm. Studies were included only if at least one lobe of the liver was covered in native and postcontrast T1 maps.
Tagged images were acquired in 3 short-axis slices positioned roughly at the LV base, midventricle, and the apex and using electrocardiographic-triggered segmented k-space fast spoiled gradientecho sequence with spatial modulation of magnetization. 27 Parallel striped tags were prescribed in 2 orthogonal orientations (0° and 90°). The MRI parameters for tagged images were field of view 360×360 mm 2 , slice thickness 10 mm, echo time 2.5 ms, flip angle 10°, matrix size 256×128, 9-phase encoding views per segment, spatial resolution 1.4×2.8×10 mm 3 , temporal resolution 25 ms, and tag spacing 7 mm. Simultaneously with T1-mapping MRI, a small subsample of MESA participants (n=36) underwent water-fat imaging using Dixon turbo gradient-echo for quantification of liver fat content. 28 This was acquired in one slice at the same location as MOLLI images that covered both the heart and liver.
MRI Data Analysis
LV volumes, LV mass, and LV ejection fraction (LVEF) were measured by semiautomated contouring of the LV epicardial and endocardial borders using commercially available software (CIM version 6.2; Auckland, New Zealand). 29 LV volumes and LV mass were indexed to body surface area.
Liver MOLLI images were processed using QMass software (version 7.6; Leiden University Medical Center, Leiden, The Netherlands). Three regions of interest were manually drawn on the native T1 images, Figure 1 . The study flowchart. AF indicates atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; ECV, extracellular volume; HF, heart failure; MESA, Multi-Ethnic Study of Atherosclerosis; and MRI, magnetic resonance imaging. Liver Fibrosis and CVD with area of ≈1 cm 2 avoiding prominent arteries, veins, and bile ducts. The regions of interest were then transposed to the postcontrast images at the same location. Levenberg-Marquardt fitting algorithm was used to calculate the native and postcontrast T1 times. 30 Partition coefficient was determined by plotting the 1/T1 time against the blood pool. 19 Extracellular volume fraction (ECV, %) was calculated as partition coefficient×(1−hematocrit)×100. 19 Higher native T1 time and higher ECV have been shown to be associated with increased fibrosis. 16, 19 Hematocrit was directly measured only in 644 participants for ECV calculation. We estimated the synthetic hematocrit for the remainder as hematocrit syn =726.19*(1/T1 precontrast blood )−0.07 and then calculated synthetic ECV. 31 The synthetic ECV strongly correlated with the actual ECV in 644 participants with directly measured hematocrit (Data Supplement). In the myocardium, T1 maps were constructed using Mass research software (MASS V2010-EXP; Leiden University Medical Center). The epicardial and endocardial borders were traced in native T1 and postcontrast images with care taken to exclude the blood pool and the epicardial fat. 19 The native T1 time and ECV in the myocardium were calculated according to the same methods as described for the liver. The native T1 time correlated with ECV in the liver and in the myocardium (r= 0.27; P<0.001 and 0.53; P<0.001, respectively).
Myocardial tagged images were analyzed using the Harmonic Phase software (Diagnosoft, Palo Alto, CA). 32 Global circumferential strain (Ecc) was determined by averaging the peak midwall segmental strains. 17 Ecc is a negative value with more negative values indicating greater regional contractile function. LA strain, LV volumes, and LA ejection fraction (LAEF) were quantified using Multimodality Tissue Tracking software (MTT, version 5.0; Toshiba, Japan). LA volumes and LAEF were extracted from volume curves and were indexed to body surface area. 33 The fat fraction of the liver from water-fat Dixon images was computed using fat and water signals at the same regions as that of the T1 maps.
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Ascertainment of the CVD Events in MESA
The procedures for ascertainment of clinical events in MESA have been described previously. 26 CHD events included myocardial infarction, resuscitated cardiac arrest, definite and probable angina (if followed by revascularization), and CHD death. AF required inhospital diagnosis according to the International Classification of Diseases, Ninth Revision, and self-reported incident AF. In this study, CVD events (any type) included AF, heart failure (HF), and CHD. Detailed criteria for end point ascertainment are provided in the Data Supplement.
Statistical Analysis
The analysis was cross-sectional relating liver native T1 time and liver ECV measured at Y10 MESA exam to history of CVD events identified between the baseline and Y10 MESA exams. Statistical analysis was performed using Stata, version 14 (Stata Corp, TX). Data are presented as mean (SD) or distribution values (%). The statistical significance was set at P<0.05. Differences in participant characteristics were tested using the Student t or Fisher exact tests.
Linear regression analyses were used to estimate the average difference in native T1 time or liver ECV at Y10 MESA exam in participants with history of CVD events compared with those without any event. Multivariable models were adjusted for demographics, alcohol use, household income, and risk factors at Y10 MESA exam that were associated with liver native T1 time or liver ECV with P<0.2 in invariable analyses. Further analyses added LV end-diastolic volume and mass (model 2) or CAC score (model 3) in multivariable models.
Furthermore, linear regression analyses were performed to assess the associations of liver native T1 time and liver ECV with MRIderived subclinical markers of cardiac structure and function.
Sensitivity analyses were performed to assess whether the association of T1-mapping-derived parameters of liver fibrosis with CVD events or its subclinical markers are dictated by cardiac structure and function or liver fat content at baseline MESA exam. This analysis included multivariable linear regression models adjusted for covariates measured at baseline MESA exam (Data Supplement).
Logarithmic transformation was applied for the variables with skewed distribution. Robust linear regression estimates were reported when the homogeneity of variance for residuals did not hold. Plausible interactions of covariates were tested. Sex-stratified analyses were performed to account for sex interaction on the associations of (1) liver native T1 time and liver ECV with LAEF at Y10 MESA exam and (2) liver ECV and LA volume index at baseline and Y10 MESA exams.
Results
Participant Characteristics
The mean age of the 2087 included participants was 68.7±9.1 with 46% males, 46.9% white, 15.2% Chinese, 23.4% black, and 14.2% Hispanics. In total, 153 individuals had a history of CVD events (78 CHD, 25 HF, and 78 AF) at the time of the Y10 MESA exam. Population characteristics are shown in Table 1 and in the Data Supplement. Compared with those with no CVD event, participants with history of a CVD event were older, more likely to be male and white, and less likely to be Chinese-American. Participants with history of CVD events had higher pulse pressure and CAC score and lower diastolic blood pressure, total cholesterol, glomerular filtration rate, and heart rate (56.2% rate of β-blocker use for those with events versus 14.9% for those without events). Subjects with history of CHD had lower HDL (Data Supplement). The proportions of participants taking antihypertensive and antihyperlipidemic drugs and those with histories of diabetes mellitus and former smoking were higher in those with a history of CVD event compared with the no-event group.
As shown in Table 1 and in the Data Supplement, participants with history of CVD events also had higher LV mass index (LVMi; except those with AF), higher myocardial ECV, lower LVEF, lower LAEF and LA maximum strain, higher LA volume index, and worsened Ecc. LV end-diastolic volume index (LVEDVi) was higher among participants with history of HF, and LV mass-to-volume ratio was higher among those with history of CHD compared with those with no prior event. Participants with history of CHD also tended to have greater CAC score. Moreover, liver native T1 time was significantly higher for participants with history of CHD and AF but not HF. Compared with the no-event group, liver ECV was significantly greater in participants with history of any type of CVD events.
Greater liver native T1 time was associated with female sex (β=−17.3; P<0.001), lower diastolic blood pressure (β=−0.3; P=0.04), higher pulse pressure (β=0.32; P<0.001), and lower cholesterol level (β=−0.15; P<0.001) in multivariable analysis. Liver ECV correlated with age (β=0.3; P=0.02), male sex (β=1.4; P<0.001), higher body mass index (β=0.6; P=0.02), lower heart rate (β=−0.1; P<0.001), lower cholesterol level (β=−0.02; P=0.003), and lower rate of cholesterol-lowering therapy (β=−0.9; P=0.03). In the validation subsample of 36 participants who underwent water-fat Dixon MRI at Y10 MESA exam, the liver fat fraction (mean, 11.6±5.1%) was inversely correlated to liver native T1 time and ECV (Figure 2 ). Computed tomography-derived liver fat content at baseline MESA exam indexed as lower attenuation value (Hounsfield unit) was not associated with liver native T1 time (β=0.2; P=0.08) and with liver ECV (β=0.001; P=0.97) at Y10 MESA exam. Liver Fibrosis and CVD
Liver Fibrosis and CVD Events
As presented in Table 2 and Figure 3 , history of CVD events was associated with 18.5 ms higher liver native T1 time (P<0.001) and 1.4% greater liver ECV (with P=0.06) after adjusting for traditional risk factors. Further adjustment for LVEDVi and LVMi did not alter these relationships substantially.
In subgroup analysis for separate types of CVD events (Table 2 ; Figure 3 ), history of AF was strongly associated with higher liver native T1 time and greater liver ECV in multivariable analyses. After adjusting for traditional risk factors, LVEDVi and LVMi, history of HF was correlated with greater liver ECV but not with higher liver native T1 time. The relationships between history of CHD and liver native T1 time and ECV remained strong after adjustment for traditional risk factors but were slightly attenuated by further adjustment for LVEDVi and LVMi (P values of 0.07-0.09).
Adjustment for CAC score attenuated the association of liver native T1 time and liver ECV with history of CHD; however, it did not alter the association of history of AF or HF with liver ECV (Table 2; Figure 3 ).
Liver Fibrosis and Subclinical Markers of CVD
As shown in Table 3 , liver native T1 time and liver ECV were strongly associated with myocardial native T1 time and myocardial ECV in multivariable analysis. Higher LVMi corresponded to higher liver native T1 time and greater liver ECV. Higher LA volume index was associated with greater liver ECV after adjusting for traditional risk factors but in men only. Further adjustment for LVEDVi and LVMi attenuated this relationship. In men, higher liver native T1 time and liver ECV corresponded to reduced LAEF. Greater liver native T1 time was also related to higher LV contractile function indexed as higher LVEF and lower Ecc. There were no statistically significant associations between CAC score and either liver native T1 time or liver ECV. 
Discussion
In this study, we show that in a multiethnic cohort free of CVD at enrollment: (1) history of CVD events was associated with T1-mapping-derived liver fibrosis indices (liver native T1 time and liver ECV); (2) the association of liver native T1 time and liver ECV was particularly strong with history of AF and moderately strong with history of CHD. Liver ECV was also strongly correlated to history of HF; (3) the association of history of CHD with liver fibrosis indices was at least in part mediated by CAC score, suggesting atherosclerosis as a key driver of this relationship; (4) T1-mapping-derived indices of liver fibrosis were also associated with LV hypertrophy and myocardial fibrosis but also greater LV systolic function. In men, indices of liver fibrosis also correlated with LA dilation and dysfunction. Previous studies on the association of liver and CVD mainly focused on hepatic steatosis. NAFLD has been strongly linked to CHD in several studies including MESA. [2] [3] [4] [5] [6] There are also reports linking NAFLD to LV dysfunction and incident AF particularly in diabetics. 9, 11 However, these findings were not replicated in all population-based large cohorts including Framingham Heart Study that showed no association between AF and hepatic steatosis 10 or the study by Markus et al, 34 which demonstrated no association between atrial fibrillation and hepatic steatosis but only with elevated liver enzymes. The data on the link between NAFLD and clinical HF is scarce in the literature. In CARDIA study (Coronary Artery Risk Development in Young Adults), NAFLD was associated with lower early diastolic relaxation velocity, higher LV filling pressure, and worse longitudinal strain, but these associations were attenuated after adjusting for visceral adiposity. 11 Also, 2 other studies demonstrated a link between hepatic steatosis with impaired myocardial perfusion and energy metabolism but with no abnormality in LV function and morphology. 7, 8 NAFLD is a spectrum ranging from >5% fat infiltration in hepatocytes (steatosis), cooccurrence of inflammation and steatosis, liver fibrosis, and ultimately cirrhosis. 12 We hypothesize that the discordance in studies on association of NAFLD with AF and LV dysfunction might be attributed to the heterogeneity in pathophysiology of fatty liver disease and the fact that this associations might be driven by liver fibrosis that coincides with liver steatosis in some but not all patients. To date, there are few studies in the literature to investigate the association of CVD and liver fibrosis, particularly in its early stages; on the contrary, Liver native T1 time and liver ECV were the independent variables in linear regression models, and the β coefficients represent the adjusted average difference in liver native T1 time or ECV in participants with history of CVD events compared with those without any event.
Model those few studies were conducted in cirrhotic patients and identified hepatic failure to be the main cause of mortality before development of symptomatic heart disease. [35] [36] [37] However, this observation is likely attributed to the entailed risk of selection bias from referral patients with advanced liver fibrosis and cirrhosis in biopsy-based studies from Figure 3 . Linear regression coefficients (CI95%) for association of liver native T1 time and liver extracellular volume fraction (ECV) with history of cardiovascular disease (CVD) events (any type), atrial fibrillation, heart failure, and coronary heart disease. Liver native T1 time and liver ECV were the independent variables in linear regression models and the regression coefficients represent the adjusted average difference in liver native T1 time or ECV in participants with history of CVD event compared with those without any event. Model 1 was adjusted for age, sex, race, income, alcohol use, and risk factors at Y10 MESA (Multi-Ethnic Study of Atherosclerosis) exam with P<0.2 in univariable analysis. Model 2 was adjusted for variables in model 1 and left ventricular mass and volume index at the Y10 MESA exam. Model 3 was adjusted for variables in model 2 and coronary artery calcium score at the Y10 MESA exam. Liver Fibrosis and CVD tertiary-care centers. 37, 38 Liver fibrosis starts much earlier, remains clinically silent, and never progresses to cirrhosis in many individuals but can result in mortality and morbidity from causes other than hepatic failure. For example, in a large population-based study on 11 154 participants from the National Health and Nutrition Examination Survey, Kim et al 15 showed that NAFLD fibrosis score (calculated from age, body mass index, glycemic state, liver enzymes, and platelet count) was a significant predictor of mortality from CVD but not hepatic failure. This study did not include AF events in the analysis and did not differentiate between CHD and HF. Using T1-mapping MRI, our results at the population level support the findings of the latter study with a robust technique and with more granularity and highlight the importance of detecting liver fibrosis and inflammation at early stages.
Native T1 time from T1-mapping MRI corresponds to the intra-and extracellular water content in hydrated fibrotic tissue, whereas ECV reflects the fraction of the volume occupied by the extracellular space in the tissue. 16, 19 In our study, history of AF and CHD was associated with both liver native T1 time and ECV, but HF correlated only with liver ECV but not with native T1 time, which could be related to smaller number of subjects with history of HF.
The association of liver fibrosis and subclinical markers of CVD in our study potentially supports its relationship with CVD events. The implication of LV hypertrophy, LA dysfunction, and myocardial fibrosis in atrial fibrillation in the literature [39] [40] [41] and their associations with liver native T1 time or liver ECV in our study might shed light into the potential mechanisms for the relationship of liver fibrosis and atrial fibrillation. The associations of liver native T1 time or liver ECV with LV hypertrophy, LA dysfunction, and myocardial fibrosis as known markers of diastolic dysfunction [42] [43] [44] also partly explain the relationship between liver fibrosis and HF, particularly diastolic dysfunction. Nevertheless, the molecular mediators of the association of liver fibrosis with AF and HF are yet to be elucidated. The activation of renin-angiotensin-aldosterone system has been implicated in myocardial fibrosis 45 and arterial stiffness, as well as in reduced arterial compliance over aging process. 46 On the other hand, renin-angiotensin-aldosterone system activation is associated with liver fibrosis. 47 In our belief, the overactivation of renin-angiotensin-aldosterone system as one of the main drivers of multiorgan fibrosis may substantially contribute to the association of liver fibrosis with AF and HF. However, this mechanistic pathway needs to be further investigated in future studies.
In this study, CAC score was not associated with liver fibrosis indices, likely because of adjustments for traditional risk factors of atherosclerosis; however, CAC score mediated the association of both liver native T1 time and ECV with history of CHD, suggesting that atherosclerosis might be an underlying key pathway.
Liver native T1 time was strongly correlated with greater LV contractile function indexed as higher LVEF and improved Ecc in this study. This is consistent with previous studies demonstrating hyperdynamic circulation in cirrhotic patients and is likely attributed to splanchnic arterial vasodilation, reduced systemic vascular resistance, and arteriovenous shunts in cirrhosis and liver fibrosis where reduced afterload protects the LV systolic function leading to preserved or even increased LVEF at rest but inability to increase the cardiac output during stress. 48 
Liver Fibrosis Assessment Tools
Studying liver fibrosis in its earlier stage is challenging. Liver biopsy remains the gold standard for staging fibrosis; however, it is associated with risks of complications and sampling error depending on the site of biopsy. 3, 15 It would be, thus, impractical if not unethical to obtain liver biopsies on asymptomatic individuals in epidemiological studies. Serum ALT level alone or in combination with other risk factors and platelet count (Fibrosis 49 NAFLD fibrosis score, 15 etc) have also been used as surrogate indicators of liver fibrosis, but they have limited sensitivity and specificity, particularly in advanced stages of fibrosis when ALT often decreases. Imaging-based modalities for assessment of liver fibrosis such as transient or magnetic resonance elastrography require sophisticated software and hardware and have limited usefulness in patients with high body mass index, narrow intercostal space, thick chest wall, or hepatic vascular congestion and fail to differentiate early stages of liver fibrosis. 13, 14 The T1-mapping MRI technique has been extensively used to study fibrosis, primarily in the myocardium. 17, 18 In simulation models, animal studies, and also clinical studies, native and postcontrast T1 times have been proven to stage histological liver fibrosis with high accuracy even in early stages and are also able to predict liver-related events over and above liver iron and fat content. [20] [21] [22] [23] [24] In an animal study in the rabbit model using a 3T MRI scanner, native T1 time increased from 372 to 497 ms with worsening stages of fibrosis. 21 Banerjee et al 50 showed that on 79 subjects with liver biopsy, the native T1 time using a 1.5-T MRI scanner increased from 717 ms in healthy volunteers to 870 and 1025 ms in patients with mild and severe liver fibrosis, respectively (correlation coefficient of 0.68). In another biopsy-based study on 81 patients, liver native T1 time was able to distinguish advanced liver fibrosis (META-VIR fibrosis score ≥F3) and cirrhosis (F4) with area under the receiver-operating characteristics curve of 0.81 and 0.92, respectively. 25 However, an understanding of the MRI acquisition parameters is key to interpreting the results correctly.
Liver T1 Mapping and Fibrosis, Fat, and Iron Content
Although T1 time is a marker of fibrosis, it can be affected by other factors such as fat or iron, particularly in the liver. The interaction of fat and T1 times is complicated and depends on several factors including magnetic field variations and MRI parameters such as repetition time and center frequency of water and fat being in-phase or out-of-phase. 23 ,51,52 With our MRI protocol in MESA, higher liver fat fraction from water-fat Dixon MRI was associated with lower liver native T1 time and liver ECV ( Figure 2 ). This association is in line with several reports in the literature 23, 25 ; however, this should not be extrapolated to other studies that may use different MRI parameters. It is also known that liver iron accumulation shortens the native T1 time. 22, 25 Hence, although liver fat and iron content can weaken the association of liver native T1 time or liver ECV with history of CVD events, the observed associations cannot be attributed to the effect of fat or iron as they have opposing effects on T1 time compared with fibrosis.
In the present study, male sex was associated with lower native T1 time but higher liver ECV. One possible explanation for this might be the attenuating effect of liver fat content on native T1 time, given that men had higher fat content than women at the MESA baseline exam (Data Supplement). But gadolinium accumulation for postcontrast T1 time could have overridden the effect of fat on T1 time and hence liver ECV became higher in men, reflecting higher degrees of fibrosis.
This study has limitations. Because this was a cross-sectional analysis, temporal and causal inferences cannot be made from the observed associations between liver fibrosis indices and CVD events. T1-mapping-derived indices of fibrosis can potentially be affected by inflammation in addition to fibrosis, and the effect of inflammation and fibrosis cannot be easily differentiated. However, liver fibrosis and inflammation are tightly connected and accompany each other and likely have similar health-related consequences. This study is subject to the selection bias arising from patients who died before Y10 MESA exam. Given the relatively small number of participants with history of HF, the analysis of association between liver native T1 time and history of HF has modest statistical power. The data on liver-related end points such as ascites or hepatic encephalopathy and liver enzyme levels were not collected in MESA. Also, because MESA participants were initially (at baseline) free of CVD, the prevalence of risk factors and liver fibrosis may not reflect that found in the general population, and extrapolation of results of the study must be considered in the context of the study design and the population examined.
In conclusion, this is, to our knowledge, the first multiethnic, population-based large study to demonstrate that early-stage subclinical liver fibrosis detected by an accurate and reproducible method (ie, T1-mapping MRI) is potentially associated with history of AF, HF, and CHD events. In this regard, the association of liver fibrosis with history of CHD is at least in part mediated by atherosclerosis and becomes attenuated and no longer significant after adjustment for CAC score. T1-mapping-derived indices of liver fibrosis are also correlated with cardiac structure and functional parameters including LV hypertrophy, LA dysfunction, and myocardial fibrosis, findings that might partly explain the mechanisms for the association of liver fibrosis with history of CVD events as well. The design of this study was cross-sectional with no potential for causal or temporal inferences, but the results of this study highlight the need for further prospective studies on the use of T1-mapping MRI for the assessment of early-stage liver fibrosis as the most amenable stage to medical management in relation to CVD.
